To limit the number of unnecessary BXs in men with elevated PSA due to benign disease or cisPCa, novel tumor markers have been developed that may aid in the decision to perform BX, e.g., pro-PSA, Prostate Health Index, prostate cancer antigen 3 (PCA3), Select MDX10,11,12,13, however, tumor markers do not provide information about the location of PCa within the prostate. This evidence concerns the gene PCA3 and neoplasm.